Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzylmorphine is a semi-synthetic opioid and the benzyl ether derivative of morphine. It was introduced to the international market in 1897 and used primarily as a moderate-strength analgesic and cough suppressant. Benzylmorphine acts similarly to codeine and ethylmorphine but is about 90% as potent as codeine by weight. Its mechanism of action is through agonism at the mu-opioid receptor (opioid receptor), leading to analgesic and antitussive effects. Benzylmorphine was formerly used for pain relief (including in eye surgery) and cough suppression but fell out of favor due to the availability of other opiates such as hydrocodone and codeine. It is now classified as a Schedule I controlled substance in the United States with no accepted medical use[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzylmorphine.